key: cord-0942577-yy8bqs9w
authors: Pedroso, Célia; Vaz, Sara; Netto, Eduardo Martins; Souza, Daniele; Deminco, Felice; Mayoral, Rafaela; Menezes, Eliana; da Cunha, Ana Patricia Amancio; Moreira-Soto, Andres; Drexler, Ian Felix; Brites, Carlos
title: Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
date: 2021-08-12
journal: Braz J Infect Dis
DOI: 10.1016/j.bjid.2021.101603
sha: 7242a99041ab0886bde4b256503caae123101338
doc_id: 942577
cord_uid: yy8bqs9w

BACKGROUND: Over-the-counter use of ivermectin amongst other drugs as SARS-CoV-2 treatment has been increasingly common, despite the lack of evidence on its clinical efficacy. OBJECTIVE: To evaluate the effect of ivermectin use on production of antibodies against SARS-CoV-2 in health care workers (HCW) diagnosed with COVID-19 and of Th1/Th2 cytokines by stimulated peripheral blood mononuclear cells of the same cohort (PBMCs). METHODS: This cross-sectional study evaluated seroconversion and neutralizing antibodies production in HCW at Complexo Hospitalar Universitário Professor Edgard Santos (Salvador, Brazil), diagnosed with COVID-19 from May to July, 2020, as well as in vitro production of antibody against SARS-CoV-2 and Th1/Th2 cytokines. Analyses were performed between December 2020 and February 2021. Participants were stratified according to the use of ivermectin (≤ 1 dose vs. multiple doses) for treatment of COVID-19. RESULTS: 45 HCW were included (62% women). Mean age was 39 years, and disease severity was similar across groups. Neutralizing antibodies were detected less frequently in multiple doses (70%) vs. ≤ 1 dose (97%) groups, p = 0.02). PBMCs of patients in multiple doses group also were less likely to produce antibodies against SARS-CoV-2 following in vitro stimulation with purified spike protein in comparison with patients in ≤ 1 dose group (p < 0.001). PBMC´s production of Th1/Th2 cytokines levels was similar across groups. Abdominal pain (15% vs 46%, p = 0.04), diarrhea (21% vs. 55%, p = 0.05) and taste perversion (0% vs. 18%, p = 0.05) were more frequently reported by participants that used multiple doses of ivermectin. CONCLUSIONS: Although there was no evidence for differential disease severity upon ivermectin use for treatment of COVID-19 it was associated with more gastro-intestinal side-effects and impairment of anti-SARS-CoV2 antibodies production, in a dose dependent manner. This potentially impacts the effectiveness of immune response and the risk of reinfection and warrants additional studies for clarifying the mechanisms and consequences of such immunomodulatory effects.

Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response Q1 X XD 1 X XC elia Pedroso D 2 X X a , D 3 X XSara Vaz D 4 X X a , D 5 X XEduardo Martins Netto D 6 X X a , D 7 X XDaniele Souza D 8 X X a , D 9 X XFelice Deminco D 1 0 X X a , D 1 1 X XRafaela Mayoral D 1 2 X X a , D 1 3 X XEliana Menezes D 1 4 X X a , D 1 5 X XAna Patricia Amancio da Cunha D 1 6 X X a , D 1 7 X XAndres Moreira-Soto D 1 8 X X b , D 1 9 X XIan Felix Drexler D 2 0 X X b,c , D 2 1 X XCarlos Brites D 2 2 X X Ivermectin is a medication of the avermectin family of com-3 pounds that is FDA-approved to treat parasite infections. 1 A 4 preliminary in vitro study on the effect of ivermectin against 5 SARS-CoV-2, 2 caused a huge increase in its over-the-counter 6 use, despite the lack of evidence of clinical efficacy. Ivermec-7 tin has a controversial immunomodulatory effect in animal 8 models, either increasing antibody production and white-9 blood-cell count or decreasing antibody levels in a dose 10 dependent response. 2,3

Seroconversion rates and durability of specific antibodies 12 in SARS-CoV-2 infection are not completely understood. 13 Impaired production of antibodies against COVID-19 can 14 affect disease severity, and likelihood of reinfection. 4−6 15 Understanding the immune response in COVID-19 patients is 16 essential for its treatment and prevention.

This study investigates the effects of self-prescribed use of 18 different ivermectin doses on rates of seroconversion for 19 SARS-CoV-2 in health care workers (HCW) diagnosed with 20 COVID-19, and the ability of HCWperipheral blood mononu-21 clear cells (PBMCs) to present an in vitro-induced IgG antibod-22 ies (IVIAP) positive test, as well as to produce Th1/Th2 23 cytokines. 24 Methods 25 In this cross-sectional study we included HCW diagnosed 26 with COVID-19 from May to July 2020 at Professor Edgard San-27 tos University Hospital, in Salvador-Brazil. SARS-CoV-2 infec-28 tion was confirmed by RT-PCR test (Charit e-Berlin protocol). 7 29 This study was approved by the Institutional Research Ethics 30 Committee (No. 4.042.620).

After signing the informed consent form, participants 32 donated 10 ml of blood to perform laboratory tests and filled 33 out a questionnaire on demographics, clinical characteristics, 34 medications and ivermectin dosages used during disease. We 35 stratified HCW by use of ivermectin (no use/single dose vs 36 multiple doses). Each dose corresponds to one 6 mg pill of 37 ivermectin.

Samples were screened using a commercially available in 39 vitro immunoassay (2019-nCoV IgG kit, SNIBE diagnostics, 40 Shenzhen, China) to detect SARS-CoV-2-specific immunoglo-41 bulins against full-length spike and nucleocapsid proteins. A 42 result greater than or equal to 1.00 AU/mL was considered 43 reactive. Next, a cPass Neutralization Antibody Detection kit 44 (Genscript, Leiden, the Netherlands) was used to detect circu-45 lating neutralizing antibodies against SARS-CoV-2 that block 46 the interaction between the receptor binding domain (RBD) of 

Professor Edgard Santos University Hospital for their partici-165 pation

The FDA-168 approved drug ivermectin inhibits the replication of SARS-169

CoV-2 in vitro

Influence of ivermectin on cellular and humoral immune 174 responses of lambs

Effect of ivermectin on 177 the cellular and humoral immune responses of rabbits

Severe acute respiratory 181 syndrome coronavirus 2Àspecific antibody responses in 182 coronavirus disease patients

Persisting neutralizing activity to SARS-CoV-2 over months in 185 sera of COVID-19 patients Viruses

Rapid 188 generation of neutralizing antibody responses in COVID

Detection of 2019 novel 192 coronavirus (2019-nCoV) by real-time RT-PCR

Macrocyclic lactones block 205 melanoma growth, metastases development and potentiate 206 activity of anti-BRAF V600 inhibitors

Personalized cancer medicine: molecular diagnostics

predictive biomarkers, and drug resistance

and dengue virus